Southpoint Capital Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Southpoint Capital Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.9M	Hold	2,744,741	–	–	0.35%	37
2025 Q4	$21.1M	Sell	2,744,741 -1,332,473	-33%	-$10.9M	0.49%	35
2025 Q3	$38.2M	Hold	4,077,214	–	–	1%	28
2025 Q2	$33.8M	Hold	4,077,214	–	–	0.85%	31
2025 Q1	$24.8M	Hold	4,077,214	–	–	0.59%	38
2024 Q4	$25.8M	Hold	4,077,214	–	–	0.6%	36
2024 Q3	$20.4M	Hold	4,077,214	–	–	0.48%	38
2024 Q2	$24.9M	Hold	4,077,214	–	–	0.62%	37
2024 Q1	$45.3M	Hold	4,077,214	–	–	0.9%	37
2023 Q4	$45.7M	Hold	4,077,214	–	–	0.98%	32
2023 Q3	$30.6M	Hold	4,077,214	–	–	0.68%	38
2023 Q2	$36M	Hold	4,077,214	–	–	0.78%	35
2023 Q1	$33.9M	Hold	4,077,214	–	–	0.77%	38
2022 Q4	$39.1M	Hold	4,077,214	–	–	1.01%	26
2022 Q3	$33M	Hold	4,077,214	–	–	0.89%	30
2022 Q2	$22.8M	Hold	4,077,214	–	–	0.65%	32
2022 Q1	$22.8M	Hold	4,077,214	–	–	0.44%	41
2021 Q4	$17.9M	Hold	4,077,214	–	–	0.34%	44
2021 Q3	$38.4M	Hold	4,077,214	–	–	0.82%	33
2021 Q2	$29.7M	Hold	4,077,214	–	–	0.52%	41
2021 Q1	$25.3M	Hold	4,077,214	–	–	0.41%	48
2020 Q4	$30.4M	Hold	4,077,214	–	–	0.53%	35
2020 Q3	$24.7M	Hold	4,077,214	–	–	0.56%	34
2020 Q2	$34M	Buy	4,077,214 +80,000	+2%	+$595K	0.83%	34
2020 Q1	$23.7M	Hold	3,997,214	–	–	0.69%	30
2019 Q4	$25.9M	Hold	3,997,214	–	–	0.93%	25
2019 Q3	$19.2M	Hold	3,997,214	–	–	0.73%	26
2019 Q2	$16M	Hold	3,997,214	–	–	0.6%	28
2019 Q1	$19.4M	Hold	3,997,214	–	–	0.82%	26
2018 Q4	$25.5M	Hold	3,997,214	–	–	1.23%	24
2018 Q3	$32.8M	Hold	3,997,214	–	–	1.27%	25
2018 Q2	$41.7M	Hold	3,997,214	–	–	1.77%	21
2018 Q1	$48.3M	Hold	3,997,214	–	–	2.14%	20
2017 Q4	$40.1M	Hold	3,997,214	–	–	1.91%	26
2017 Q3	$44.3M	Buy	+3,997,214	New	+$46.4M	1.82%	19

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Southpoint Capital Advisors's FENC Position: Q1 2026 in Review

Southpoint Capital Advisors held its Fennec Pharmaceuticals (FENC) position steady in Q1 2026 at 2,744,741 shares worth $16.9M. The position accounts for 0.35% of the portfolio, ranked #37.

Southpoint Capital Advisors first reported a position in FENC in Q3 2017 and has held it in 35 quarters since. The position peaked at $48.3M in Q1 2018. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

Southpoint Capital Advisors held 2,744,741 shares of Fennec Pharmaceuticals worth $16.9M as of Q1 2026.
Southpoint Capital Advisors left its Fennec Pharmaceuticals share count unchanged in Q1 2026.
Fennec Pharmaceuticals made up 0.35% of Southpoint Capital Advisors's portfolio in Q1 2026, its #37 holding.
Southpoint Capital Advisors first reported a position in Fennec Pharmaceuticals in Q3 2017 and has held it in 35 quarters since.
Southpoint Capital Advisors's Fennec Pharmaceuticals position peaked at $48.3M in Q1 2018.
90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Southpoint Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.